Percutaneous transplantation of human umbilical cord-derived mesenchymal stem cells in a dog suspected to have fibrocartilaginous embolic myelopathy

The use of human umbilical cord blood-derived mesenchymal stem cells for cell transplantation therapy holds great promise for repairing spinal cord injury. Here we report the first clinical trial transplantation of human umbilical cord (hUCB)-derived mesenchymal stem cells (MSCs) into the spinal cor...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Wook-Hun, Park, Seon-Ah, Lee, Jae-Hoon, Chung, Dai-Jung, Yang, Wo-Jong, Kang, Eun-Hee, Choi, Chi-Bong, Chang, Hwa-Seok, Kim, Dae-Hyun, Hwang, Soo-Han, Han, Hoon, Kim, Hwi-Yool
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Veterinary Science 2013
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3885746/
https://www.ncbi.nlm.nih.gov/pubmed/23820160
http://dx.doi.org/10.4142/jvs.2013.14.4.495
Descripción
Sumario:The use of human umbilical cord blood-derived mesenchymal stem cells for cell transplantation therapy holds great promise for repairing spinal cord injury. Here we report the first clinical trial transplantation of human umbilical cord (hUCB)-derived mesenchymal stem cells (MSCs) into the spinal cord of a dog suspected to have fibrocartilaginous embolic myelopathy (FCEM) and that experienced a loss of deep pain sensation. Locomotor functions improved following transplantation in a dog. Based on our findings, we suggest that transplantation of hUCB-derived MSCs will have beneficial therapeutic effects on FCEM patients lacking deep pain sensation.

Ejemplares similares